网站大量收购闲置独家精品文档,联系QQ:2885784924

我院151例严重的药品不良反应报告分析.pdf

  1. 1、本文档共3页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
我院151例严重的药品不良反应报告分析

我院151例严重的药品不良反应报告分析 * # 尚丹婷 ,李 洵,陈美玲,许惠英,朱红球(广东省人民医院/广东省医学科学院药学部,广州 510120) 中图分类号 R969.3;R978.1 文献标志码 A 文章编号 1001-0408(2015)11-1514-03 DOI 10.6039/j.issn. 1001-0408.2015.11.25 摘 要 目的:了解我院严重药品不良反应(ADR )发生的特点及规律,为促进临床安全、合理用药提供参考。方法:对我院 2010-2013年上报的151例严重的ADR 报告进行统计、分析。结果:发生2例疑似ADR 死亡病例;男性和老年患者严重的ADR 发生率较高,分别占53.64%和44.37%;口服给药引起的严重的ADR 占47.68%,静脉给药占45.03%;在涉及的所有药品中,抗微 生物药和抗肿瘤药各占18.54%,循环系统药占14.57%;严重的ADR 累及器官/ 系统以血液系统最多,占22.16%。结论:临床应关 注严重的ADR 涉及药品及其引起机体损害的临床表现,加强用药监测,减轻或避免严重的ADR 的发生;药品生产企业应加强产 品上市后安全性研究及ADR 跟踪监测,完善产品说明书,增加相关安全性信息。 关键词 严重的不良反应;合理用药;死亡;老年患者 Analysis of 151Cases of Serious Adverse Drug Reaction Reports in Our Hospital SHANG Dan-ting ,LI Xun ,CHEN Mei-ling ,XU Hui-ying ,ZHU Hong-qiu (Dept. of Pharmacy ,Guangdong People ’s General Hospital/Guangdong Academy of Medical Sciences ,Guangzhou 510120,China ) ABSTRACT OBJECTIVE :To explore the characteristics and regular patterns of serious adverse drug reactions (ADR )and pro- vide reference for the safety drug use in clinic. METHODS :151reports of serious ADR in our hospital from 2010to 2013were sta- tistically analysis. RESULTS :2 cases were suspected as death ;the incidences of ADR in male and elderly patients were high ,ac- counting for 53.64% and 44.37%,respectively ;serious ADR caused by oral and intravenous administration were respectively 47.68%and 45.03%. In all the involving drugs ,the ratio of anti-microbial drugs and anti-tumor drugs was 18.54%for both ,and the drugs of circulatory system was 14.57%. Blood system had large proportion and the most serious ADR involving organs or sys- tems (22.16%). CONCLUSIONS :Clinic should pay attention to the serious ADR drugs and their clinical manifestations ,strength- en drug monitoring ;It is suggested that the manufacturers should strengthen the safety research and ADR tracking and monitoring after t

文档评论(0)

hhuiws1482 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

版权声明书
用户编号:5024214302000003

1亿VIP精品文档

相关文档